
Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
RDY is up 4.09% today. Volume is 4.12M vs a 30-day average of 3.15M (1.31x).

Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.

Dr. Reddy's Laboratories (NYSE:RDY) reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower No…

Dr Reddy’s Laboratories (NYSE:RDY) reported second-quarter financial results on Friday. The transcript from the company’s second-quarter earnings call has been provided below.This…
Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.16 by 25 percent. This is a 36.84 percent d…